HCA Healthcare, Inc. $HCA Shares Sold by Dynamic Technology Lab Private Ltd

Key Points

• Dynamic Technology Lab Private Ltd reduced its stake in HCA Healthcare by 50.7%, selling 912 shares and leaving it with 888 shares valued at approximately $307,000.
• Several large investors, including Cheviot Value Management and Saudi Central Bank, have recently acquired new positions in HCA Healthcare, indicating institutional interest in the company.
• A recent analyst report from Cantor Fitzgerald set a target price of $444.00 for HCA shares, reaffirming an "overweight" rating, while other firms have issued varying target adjustments, reflecting mixed sentiment among analysts.

Dynamic Technology Lab Private Ltd reduced its position in HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 50.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 888 shares of the company's stock after selling 912 shares during the period. Dynamic Technology Lab Private Ltd's holdings in HCA Healthcare were worth $307,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Cheviot Value Management LLC acquired a new position in HCA Healthcare during the first quarter worth $26,000. Saudi Central Bank acquired a new position in HCA Healthcare during the first quarter worth $26,000. WPG Advisers LLC acquired a new position in HCA Healthcare during the first quarter worth $27,000. Atwood & Palmer Inc. acquired a new position in HCA Healthcare during the first quarter worth $28,000. Finally, Bartlett & CO. Wealth Management LLC raised its position in HCA Healthcare by 888.9% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 89 shares of the company's stock worth $31,000 after acquiring an additional 80 shares during the period. 62.73% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on HCA shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $444.00 target price on shares of HCA Healthcare in a report on Tuesday, August 26th. Morgan Stanley dropped their target price on shares of HCA Healthcare from $410.00 to $400.00 and set an "equal weight" rating for the company in a report on Monday, July 28th. Truist Financial upped their target price on shares of HCA Healthcare from $390.00 to $415.00 and gave the stock a "buy" rating in a report on Wednesday, July 16th. JPMorgan Chase & Co. upped their target price on shares of HCA Healthcare from $360.00 to $370.00 and gave the stock a "neutral" rating in a report on Monday, August 4th. Finally, Barclays dropped their price objective on shares of HCA Healthcare from $416.00 to $390.00 and set an "overweight" rating for the company in a report on Monday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, HCA Healthcare presently has an average rating of "Moderate Buy" and an average target price of $403.17.

Insiders Place Their Bets

In other HCA Healthcare news, EVP Michael S. Cuffe sold 3,836 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the completion of the transaction, the executive vice president owned 31,503 shares of the company's stock, valued at $13,194,716.52. This trade represents a 10.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.30% of the stock is currently owned by company insiders.

HCA Healthcare Trading Up 0.7%

Shares of HCA opened at $405.54 on Friday. The company has a current ratio of 0.98, a quick ratio of 0.86 and a debt-to-equity ratio of 69.07. The firm has a market capitalization of $94.89 billion, a P/E ratio of 17.05, a P/E/G ratio of 1.27 and a beta of 1.41. The firm has a 50-day moving average price of $382.88 and a 200 day moving average price of $362.77. HCA Healthcare, Inc. has a 12-month low of $289.98 and a 12-month high of $420.98.

HCA Healthcare (NYSE:HCA - Get Free Report) last announced its earnings results on Friday, July 25th. The company reported $6.84 earnings per share for the quarter, topping the consensus estimate of $6.20 by $0.64. The company had revenue of $18.61 billion during the quarter, compared to analyst estimates of $18.49 billion. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. HCA Healthcare's revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the firm posted $5.50 earnings per share. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. Sell-side analysts forecast that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Tuesday, September 16th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Tuesday, September 16th. HCA Healthcare's dividend payout ratio (DPR) is 12.11%.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.